GLUE — Monte Rosa Therapeutics Share News
0.000.00%
Last trade - 00:00- $947.83m
- $326.73m
- $123.67m
U.S. STOCKS ON THE MOVE-Union Pacific, Corteva, Novocure
U.S. STOCKS ON THE MOVE-Tesla, Ocugen, Union Pacific
Monte Rosa soars after $5.7 billion drug development deal with Novartis
Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics (updated)
Novartis, Monte Rosa strike $5.7 billion drug development deal
Monte Rosa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 collaboration revenue surges
Monte Rosa Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Monte Rosa Therapeutics Announces First Subjects Dosed In Phase 1 Study Of Mrt-8102, A Nek7-Directed Molecular Glue Degrader For The Treatment Of Multiple Inflammatory Diseases
Brief: Monte Rosa Therapeutics Announces FDA Clearance Of Ind Application For Mrt-8102
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Monte Rosa Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose
Brief: Monte Rosa Therapeutics Q4 Operating Expenses USD 47.643 Million
U.S. RESEARCH ROUNDUP-Bath & Body Works, Datadog, Savers value Village
Brief: Monte Rosa Therapeutics Q3 Pretax Profit USD -23.788 Million
U.S. STOCKS ON THE MOVE-Monte Rosa, EyePoint Pharma, Shake Shack
Monte Rosa Therapeutics surges on licensing deal with Novartis
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs